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ABSTRACT 
 
   Patients and methods: From 1993 to 2001 thirty-two children underwent bone marrow transplan-
tation (BMT) for acute lymphoblastic leukaemia (ALL) (12 in I complete remission /I CR/ of high-risk 
/HR/ ALL, and 20 in II CR after early bone marrow or combined bone marrow/organ relapse). Except 
for two syngeneic all others were matched sibling donor transplants. All patients (pts) were conditioned 
with fractionated total body irradiation (FTBI) at a total dose of 12,6 Gy, given in 8 fractions during 
4 days with lung shielding (9,4 Gy) and cyclophosphamide (CY) 60 mg/kg i.v for 2 days (total dose 
120 mg/kg) (n = 1 in I CR and n = 11 in II CR) or etoposide (VP) 60 mg/kg i.v (n = 11 in I CR and n = 9 
in II CR). Patients in I CR were given 1,1–4,9x108 nucleated cells /kg (med. 2,7x108/kg), while pts 
in II CR 1,9–4,0x108 nucleated cells/kg (med. 2,7x108/kg). For graft versus host disease (GvHD) 
prevention cyclosporin A (CsA) 3 mg/kg/d i.v was administered alone in 22 pts (n = 9 in I CR and 
n = 13 in II CR) or in combination with “short” methotrexate +/- prednisone in 8 pts (n = 3 in I CR and 
n = 5 in II CR). Two pts transplanted with syngeneic BM received no GvHD prevention. The regimen 
related toxicity (RRT) was graded according to the system developed by Bearman et al. (1988).  
   Results: Only mild or moderate expression of RRT was observed (GI toxicity I0 - 80%, II0 - 4%; 
stomatitis I0 - 40%, II0 - 20%;  hepatic toxicity I0 - 28%; renal, bladder and cardiac toxicity I0 - 4%) and 
no transplant related deaths occurred (TRM = 0%). Among 12 pts transplanted in I CR only one child 
relapsed 4 months from BMT, while the remaining 11 pts are alive in continuous complete remission 
(CCR) with a median follow-up of 33 months (range 6 to 66 months) and 92% probability of a 5-year 
event free survival (pEFS). Of 20 children transplanted in II CR 6 relapsed 1-14 months from BMT 
(median 6,5 months). Thirteen of them remain in CCR with a median follow-up of 19.5 months (range 
1 to 96 months) and with 66% probability of a 8-year EFS.  
   Conclusions: 1. In children with ALL the FTBI-12,6 Gy-containing regimen is well tolerated without 
life-threatening toxic complications. 2. The FTBI-12,6 Gy-containing regimen demonstrates very good 
antileukaemic efficacy for HR-ALL in I CR, but only limited efficacy for ALL in II CR. 3. In the context of 
good tolerance of FTBI in a total dose of 12,6 Gy and its limited antileukaemic efficacy in children with 
ALL in II CR the escalation of FTBI total dose from 12,6 Gy to at least 13,2 Gy appears to be justified 
in those children.  
 
   Key words: acute lymphoblastic leukaemia, fractionated total body irradiation, allogeneic bone 
marrow transplantation. 
 
INTRODUCTION 
 
   Acute lymphoblastic leukaemia (ALL) 
remains the most frequent malignancy 
in children, comprising 30% of all child-
hood neoplasms [1]. Thanks to present-
day chemotherapy about 85% children 
with ALL from a standard-risk group and 
70% from a high-risk group have a chance 
to  be  cured  [2, 3, 4].   On  the  contrary, 
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in the case of relapsed ALL – especially 
in the case of a very early or early bone 
marrow relapse - the probability of susta-
ined remission is significantly lower com-
pared with primary ALL [5,6]. Therefore, 
in the majority of children in II CR of ALL, 
and also in those 8-10% who demonstrate 
very high-risk of relapse in I CR, bone 
marrow transplantation (BMT) is perfor-
med as a consolidation of conventional 
chemotherapy to improve the results 
of the treatment. For these reasons, ALL is 
the most frequent (53,4%) indication 
for BMT in childhood [7,8]. However, it is 
not yet established which preparative re-
gimen for BMT assures in children with 
ALL the best results, i.e. the minimal re-
gimen related toxicity along with maximal 
anti-leukaemic efficacy. According to our 
preliminary observations, the busulfan-
based conditioning regimen – despite 
suggestions by other authors [9] - provided 
worse results than the total body irra-
diation (TBI)-containing regimen in chil-
dren transplanted for ALL in II CR [10]. 
Therefore, since January 1993 all children 
over 2 years of age suffering from ALL 
and demonstrating indications for BMT 
have been conditioned for transplantation 
by fractionated TBI (FTBI) at a total dose 
of 12,6 Gy with lung shielding (9,4 Gy), 
supplemented with cyclophosphamide 
or etoposide. 
 
PATIENTS AND METHODS 
 
Patients 
   From 1993 to 2001, thirty-two children 
(12 females and 20 males) aged from 
4 to 18 (median 10,5 years) underwent 
BMT for ALL.  
   Twelve patients, who demonstrated 
a very high risk (VHR) of leukaemia rela-
pse (i.e. t(9; 22) or t(4; 11), and/or poor 
prednisone response, and/or no CR on 
day 33 of induction treatment according 
to the New York Protocol [11]), were 
transplanted in I CR. Transplantation was 
performed at least 3 months from 
the diagnosis (range 3-11 months; median 
6 months).  
   Twenty patients obtained transplant 
in II CR after a very early (n = 2), early 
(n = 9) or late (n = 9) bone marrow 
(n = 18) or combined bone marrow/organ 
(n = 2) relapse. The Relapse was  treated 
according to the ALL-REZ-BFM Protocols 
[6,12]. Children in II CR underwent 
transplantation 1 to 12 months from the re-
lapse (median 5 months). 
 
Patient/donor HLA typing 
   Except for two transplants from synge-
neic twins, all other children were trans-
planted with allogeneic bone marrow from 
genotypically HLA-identical siblings.  
 
Preparative regimen 
   All patients were conditioned for BMT 
by FTBI of a total dose of 12,6 Gy given 
in 8 fractions during 4 consecutive days 
(2 fractions/day) with reduction to 9,4 Gy 
in the lungs. Fifteen patients were irra-
diated with a Cobalt-60 unit, while 17 with 
a linear accelerator Mevatron with 15 MeV 
photons. A dose of 8.2 Gy was delivered 
from six lateral fields, and a dose of 4.4 Gy 
from four anterior-posterior fields. For Co-
balt-60, the lateral fields were set at a sour-
ce to the skin distance (SSD) of 275 cm 
with the dose rate in the midline 
of 6,67÷9,01•10-2 Gy/min, and AP/PA fields 
were set at 183 cm with 17.75÷27,90•10-2 
Gy/min, respectively [13,14]. For the linear 
accelerator, the lateral fields were set 
at the SSD of 307 cm with the dose rate 
of 4,25•10-2 Gy/min, and AP/PA fields 
at 206 cm with 10,65•10-2 Gy/min, respecti-
vely. The method of FTBI has been des-
crybed in detail elsewhere [15]. 
   In 12 children (1 in I CR and 11 in II CR) 
FTBI was followed by cyclophosphamide 
(CY) 60 mg/kg/day i.v for 2 days (total 
dose 120 mg/kg), while in the remaining 
20 patients (11 in I CR and 9 in II CR) 
FTBI was supplemented with etoposide 
(VP-16) 60 mg/kg i.v.  
 
Source and number of transplanted 
cells 
   All children were transplanted with bone 
marrow. Patients in I CR were given 
1,1-4,9x108 NC/kg (med. 2,7x108/kg), 
whereas those in II CR obtained 
1,9–4,0x108 NC/kg (med. 2,7x108/kg).  
 
Graft-versus-host disease prophylaxis 
and grading 
   For graft versus host disease (GvHD), 
prevention cyclosporin A (CsA) was admi-
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nistered alone in 22 patients (9 in I CR and 
13 in II CR) or in combination with “short” 
methotrexate (MTX) +/- prednisone (PRED) 
in 8 pts (3 in I CR and 5 in II CR). CsA 
administration started 36 hours before 
transplantation and was continued intra-
venously until the patient could tolerate 
the oral form of the drug. The CsA level 
was monitored three, times weekly and 
the dosage was adjusted to maintain 
the whole blood level of 100 +/- 25 ng/ml 
until day +120 and then slowly tapered 
until day +150. Two patients transplanted 
with syngeneic bone marrow received 
no GvHD prevention.  
   Acute and chronic GvHD was graded 
according to standard criteria [16,17]. 
 
Regimen-related toxicity grading  
   Regimen-related toxicity (RRT) was gra-
ded according to the criteria developed 
by Bearman et al. [18]. 
 
Supportive therapy 
   All patients had indwelling multilumen 
central venous catheter (usually of the Sel-
dinger or Broviac type) and were nursed 
in steril tents with a laminar flow of HEPA-
filtered air. Sterile care and oral as well 
as gut decontamination were applied. 
All children received intravenous 7-S im-
munoglobulins. In the majority of patients 
rHu-G-CSF was administered starting be-
tween day +7 and +10 after transplan-
tation. Irradiated and leukocyte-depleted 
blood products were given to all children. 
Since 1995 a pre-emptive treatment with 
gancyclovir have been used in patients de-
monstrating reactivation of CMV infection 
based on weekly CMV-DNA-PCR scree-
ning results. 
 
Outcome measures 
   The outcome measures were: (1) en-
graftment (ANC ≥ 0,5x109/L on three 
consecutive days and/or platelet count 
≥ 20x109/L without transfusion on 7 conse-
cutive days), (2) graft failure (primary fai-
lure, i.e. failure to reach ANC ≥ 0,5x109/L 
for at least 28 days after transplantation; 
secondary failure i.e. decrease of ANC 
to below 0,2x109/L for at least 3 consecu-
tive days after initial engraftment), 
(3) transplant-related mortality (death 
in continuous complete remission), 
(4) acute and chronic GvHD (see above: 
Graft-versus-host disease prophylaxis and 
grading), (5) leukemia relapse (> 5% 
blasts in the bone marrow post-transplant), 
and (6). event-free survival.  
 
Informed consent 
   The risk related to the treatment proce-
dure was explained in detail to parents 
and older children, and then informed 
consent and written agreement were 
obtained. 
 
Statistical methods 
   For statistical evaluation of the outcome 
after BMT, the Kaplan-Meier plots for time-
dependent analyses of event-free survival 
were used. 
 
 
 
RESULTS 
 
Engraftment results 
   In all children sustained engraftment 
was achieved with a median time to 
ANC ≥ 0,5x109/L of 11 days (range 9 -16), 
i.e. no primary or secondary graft failure 
occurred. 
 
Regimen-related toxicity (RRT) 
   According to the Bearman criteria [18] 
only mild or moderate expression of RRT 
was observed with the maximal RRT 
experienced by, patients of grade II. 
Toxicity was most common in the gastro-
intestinal tract, mouth and liver, i.e. gastro-
intestinal toxicity I0 – 81,3% (26/32), 
II0 – 3,1% (1/32); stomatitis I0 – 40,3% 
(13/32), II0 – 18,8% (6/32); hepatic toxicity 
I0 - 28% (9/32); renal, bladder and cardiac 
toxicity I0 – 3,1% (1/32). 
 
Acute and chronic GvHD 
   Acute GvHD grade II-IV was observed 
in 10 (30,3%) children, while chronic GvHD 
was diagnosed in 4 (12,5%) patients. In all 
children acute and/or chronic GvHD resol-
ved after immunosuppressive treatment 
with CsA and corticosteroids and/or anti-
thymocyte globulin and/or azathioprine. 
 
Transplant-related mortality 
   No transplant related deaths occurred 
(TRM = 0%).  
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 Fig. 1. The probability of event-free survival (pEFS) in children with ALL transplanted in first or second complete remission (CR) 
after conditioning by fractionated total body irradiation and cyclophosphamide or etoposide. 
 
 
 
Leukaemia relapse and event-free 
survival 
   Among 12 patients transplanted in I CR 
only one child relapsed after 4 months 
from BMT, while the remaining 11 patients 
are alive in continuous complete remission 
(CCR) and with a median follow-up 
of 33 months (range 6 to 66 months) 
and with 92% probability of a 5-year EFS 
(Fig. 1). 
   Six of 20 children transplanted in II CR 
relapsed from 1 to 14 months, from BMT 
(median 6,5 months). Fourteen of them 
still remain in CCR with a median of fol-
low-up of 19,5 months (range 1 to 96 
months) and with 66% probability 
of a 8-year EFS (Fig. 1).  
 
DISCUSSION 
 
   Indications for allogeneic BMT (allo-BMT) 
and its place in the treatment of childhood 
ALL should be considered in the context 
of chemotherapy results. Therefore, 
the allo-BMT is justified only in those 
patients with ALL for whom chemotherapy 
usually fails to be curative, i.e. in 8-10% 
of children in I CR, who demonstrate 
factors of a very high risk of chemotherapy 
failure, such t(9; 22) or t(4; 11), and/or 
poor prednisone response, and/or no CR 
at day 33 of induction treatment, and 
in the majority of children in II or sub-
sequent CR after leukaemia relapse 
[19,20]. In those children the allogeneic 
BMT is performed for the consolidation 
of conventional chemotherapy to improve 
the overall results of the treatment. 
However, the treatment failures occur 
even after allo-BMT and therefore, further 
optimisation of the transplant procedure is 
necessary.  
   In children with ALL the allo-BMT out-
come is affected by numerous transplant-
related factors, such as donor-recipient 
HLA-match, source and number of trans-
planted haematopoietic cells, in vitro pro-
cessing of transplanted material before 
transplantation, GvHD prophylaxis and 
GvHD occurrence and supportive therapy 
[21,22]. However in the context of a rather 
minor role of graft-versus-leukaemia effect 
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in ALL [23] the conditioning regimen 
seems to be the most important factor. 
Nevertheless, until now it has not been 
established, which conditioning regimen 
for BMT in children with ALL assures 
the best outcome, i.e. the minimum re-
gimen related toxicity along with the ma-
ximum anti-leukaemic efficacy.  
   According to our preliminary obser-
vations, the busulfan-based conditioning 
regimen – despite suggestions by other 
authors [9] - provided worse results than 
the total body irradiation (TBI) -containing 
regimen in children transplanted for ALL 
in II CR [10]. Recently, this observation 
has been confirmed in the report 
of the International Bone Marrow Trans-
plant Registry concerning 176 patients 
conditioned by BU plus CY and 451 pa-
tients who received cyclophosphamide 
plus TBI from 144 institutions [24]. 
Besides, Carpenter et al. [25] have de-
monstrated that the preparative regimen 
combining BU and CY with single dose 
melphalan does not lead to a better out-
come than that in a control group trans-
planted using TBI and CY, because of un-
acceptable toxicity (42% of the children 
dying of RRT). Increased incidence 
of a veno-occlusive disease, haemorrhagic 
cystitis and RRT mortality in children with 
ALL, especially in patients with advanced 
leukaemia, who received BU instead 
of TBI have also been reported by the in-
vestigators from the Nordic BMT Group 
[26].  
   Therefore, nowadays it is being reco-
mmended that children with ALL should be 
prepared for allo-BMT with TBI-containing 
regimens. However, further studies are 
needed on the optimal methods of TBI 
and its total dose, as well as on chemo-
therapeutic agents used in preparative 
regimen in addition to TBI. In our centre 
since January 1993 all children over 
2 years of age suffering from ALL with 
indications for BMT are conditioned 
for transplantation by fractionated TBI 
(FTBI) at a total dose of 12,6 Gy with lung 
shielding (9,4 Gy) given in 8 fractions du-
ring 4 consecutive days (2 fractions/day) 
plus CY or VP-16. Among 12 patients 
transplanted for VHR-ALL in I CR only one 
child relapsed 4 months from BMT, while 
the remaining 11 patients are alive in CCR 
with a median follow-up of 33 months 
(range 6 to 66 months) and with 92% 
probability of a 5-year EFS. All this proves 
that in children with VHR-ALL allogeneic 
BMT performed in I CR is associated with 
an improved outcome in comparison with 
the results of conventional treatment alone 
(30-47% probability of 3-4-year EFS) [4,27]. 
The role of the myeloablative regimen 
consisting of TBI plus CY and allogeneic 
BMT performed in I CR in children su-
ffering from ALL with unfavourable bio-
logical features has been demonstrated 
for the first time in an early report from 
the French BMT Group [28]. In 32 pa-
tients a disease-free survival (DFS) 
was 84,4% with a median follow-up 
of 30 months. The investigators from 
the Nordic BMT Group confirmed a low 
toxic death rate and a low relapse rate 
(DFS at 10 years was 73%) in transplant 
recipients  undergoing allogeneic BMT 
in I CR of high-risk ALL (n = 22) condi-
tioned by TBI and Cy [29]. Recently, 
preliminary results of prospective study 
on allogeneic BMT versus chemotherapy 
for VHR-ALL in I CR conducted by 
the EBMT Paediatric Working Party and 
I-BFM-SG have been published [30]. 
Seven European countries participated 
in this study, 238 patients received che-
motherapy, while 72 patients underwent 
BMT (45 from HLA identical sibling 
donors, 20 from unrelated donors, and 
12 from alternative family donors). In this 
study, children were conditioned for BMT 
by FTBI at a total dose of 12 Gy given 
in 6 fractions (2 fractions/day) during three 
consecutive days, followed by VP-16 
(60 mg/kg/day). Six (13,3%) of 45 children 
that underwent allogeneic BMT from HLA 
identical sibling donors died in CCR 
as a result of transplant related com-
plications, while leukaemia relapse occu-
rred as a 10 (22,2%) of them. The overall 
median follow-up was 27 months (range 
0-55 months) with 58,4% of DFS pro-
bability at 2 years. 
  In the context of the data from the lite-
rature one could conclude that our results 
are at least comparable or even somewhat 
better than those reported by other inves-
tigators. Therefore, we can recommend 
a preparative regimen consisting of FTBI 
of a total dose of 12,6 Gy given in 8 fra- 
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ctions over 4 days plus VP-16 
(60 mg/kg/day) as a well-tolerated regi-
men and one that demonstrates satis-
factory antileukemic efficacy in children 
with VHR-ALL in I CR. Our group of pa-
tients was relatively small, but it was 
selected according to uniform well-esta-
blished criteria and uniformly treated 
at each phase of the procedure, chara-
cterized by a relatively long follow-up 
(up to 66 months, median 33 months). 
   As already mentioned the conventional 
regimen consisting of TBI and CY seems 
superior to the combination of BU and CY 
in ALL [10,24]. However, no randomised 
studies have been made to compare 
the outcome of allogeneic BMT in children 
with ALL in II CR prepared for trans-
plantation with different FTBI-containing 
conditioning regimens. Uncontrolled trials 
using TBI and cytarabine [31], TBI, cyta-
rabine and melphalan [32], and hyper 
fractionated TBI and CY [33] claim to have 
reduced the risk of relapse. The substi-
tution of VP-16 for CY in the preparative 
regimen was studied by the investigators 
at the City of Hope National Medical 
Centre in Duarte (California, USA), and 
it was suggested that the combination 
of VP-16 and TBI might be associated with 
a decreased relapse rate in patients with 
ALL [34,35]. FTBI (12 Gy) and VP-16 
(60 mg/kg/day) have also been used by 
German investigators in 23 children with 
ALL in II CR [34]. Their data also suggest 
the reduced relapse rate in these patients 
(7-year event-free survival 52%, with me-
dian follow-up 3,4 years), when compared 
with those who received TBI and other 
chemotherapeutic agents (6-year DFS 
40 +/- 3%; Barret et al., 1994) [37]. Howe-
ver, further investigation of the contribution 
of the VP-16 to the outcome is needed 
to determine if its use reduces post-
transplant relapse. At our centre a com-
parable group of children (n = 20) 
underwent allogeneic BMT for ALL in II 
CR. They were prepared for BMT with 
the same dose of VP-16, i.e. 1 x 60 mg/kg 
(n = 9) or CY 2 x 60 mg/kg (n = 11), but 
with a somewhat higher total dose of FTBI, 
i.e. 12,6 Gy vs 12 Gy given in 8 vs. 6 fra-
ctions over 4 vs 3 days. Not a single child 
died because of transplantrelated compli-
cations and the treatment failures obser-
ved were exclusively related to leukaemia 
relapse, which occurred in 6 (30%) pa-
tients within 1-14 months (median 
6,5 months) from BMT. Fourteen children 
remain in CCR with a median follow-up 
of 19,5 months (range 3 to 100 months) 
and with 66% probability of the a 8-year 
event-free survival, i.e. the results obtai-
ned in our group of patients are at least as 
good as those reported by German 
investigators. However, in the context 
of good tolerance of FTBI in a total dose 
of 12,6 Gy and its still limited anti-
leukaemic efficacy in children with ALL 
in II CR, we conclude that the escalation 
of FTBI total dose from 12,6 Gy to at least 
13,2 Gy appears to be justified in those 
children. In addition, the total dose of FTBI 
could be individualized according to risk 
factors of FTBI-related toxicity observed 
before transplantation, the level of residual 
disease prior to preparative regimen [36], 
and the measurements of individual leu-
kaemic cell radiosensitivity [39]. Improve-
ment in the allogeneic BMT outcome 
in children with ALL will be possible 
in future if the above measures are taken 
together with others such as the use 
of chemotherapeutic agents in preparative 
regimen according to the results of a drug 
resistance profile, modulation of drug re-
sistance of residual leukaemic cells, pro-
tection and induction of graft-versus-
leukaemia effect as well as introduction 
of adoptive immunotherapy according 
to quantitative results of molecular mo-
nitoring of post-transplant haematopoietic 
chimerism and minimal residual disease. 
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